Clinical trial · no report yet · Phase 2
PIVOT-10
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer
- NCT03785925 ↗
- Completed
- Nektar Therapeutics
- 6 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| YouTube | 5 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Single-Arm Study of Bempegaldesleukin (NKTR-214) in Combination With Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Urinary Bladder Neoplasm; Neoplasm Metastasis
- Interventions
- Bempegaldesleukin; Nivolumab
- Arms
- Combination of bempegaldesleukin (NKTR-214) + nivolumab · Experimental
- Enrollment
- 192
- Primary outcomes
- Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Per Blinded Independent Central Review (BICR) in Patients Whose Tumors Have Low Programmed Cell Death Ligand (PD-L1) Expression
- Sponsor
- Nektar Therapeutics with Bristol-Myers Squibb
- Start
- Apr 29, 2019
- Primary completion
- Feb 9, 2022
- Results posted
- Yes
- Registry record
- NCT03785925 · updated Mar 28, 2023